HARBIN, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. (“China Sky One Medical” or “the Company”) , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People’s Republic of China (“PRC”), today announced that the Company has begun to export its Pain Relief patch to Canada. The first order included 40,000 patches, which are now available in some stores and supermarkets in Vancouver.
“We are excited to have our Pain Relief patches enter the Canadian market and see a lot of opportunity,” commented Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. “We are now working with sales agent to estimate future sales volumes. Looking forward, we will put more effort into expanding distribution of our products into North American markets as we seek to further increase profitability and shareholder value.”
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (“TDR”), Harbin First Bio- Engineering Company Limited (“First”), Heilongjiang Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin Chuang Pharmaceutical Company (“Jin Chuang”) the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of market expansion. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
SOURCE China Sky One Medical, Inc.
CONTACT: China Sky One Medical, Inc. - Mr. Stanley Hao, CFO,
+86-0451-5399-4069, stanleyhao@cski.com.cn, or Investor Relations Contact -
CCG Investor Relations, Mr. Crocker Coulson, President, +1-646-213-1915,
crocker.coulson@ccgir.com
Web site: http://www.cski.com.cn/
